MedPath

Tobacco Intensive Motivational and Estimate Risk

Not Applicable
Completed
Conditions
Severe Mental Disorder
Smoking Cessation
COPD
Interventions
Device: personalized information about lung damage
Registration Number
NCT03583203
Lead Sponsor
Hospital Universitario Reina Sofia de Cordoba
Brief Summary

Randomized, open label, prospective study with a 12-month follow-up period. The primary objective evaluates the effectiveness of an intensive anti-smoking programme that informs patients of their individual risk of lung damages and the possibilities of prevention. The main measurement will be having given up smoking in month 12, measurement of self-reported abstinence on the 7 previous days and confirmed by a CO-oximeter test\< 10 ppm, between the intervention and control group. A total of 9 urban and rural mental health centres will participate in the study. The intervention group will undergo spirometry and presence and the degree of respiratory obstruction will be assessed. Participants will be given individual information to generate a motivational message about the possibilities of prevention and the information will be maintained for three months by sending text messages (SMS) to their mobile phones. The efficacy of the method and the pulmonary damage variables will be evaluated: smoking cessation at the end of follow-up will be confirmed by cooximetry, and the COPD diagnosis and the severity of the staging for disease will be assessed

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
230
Inclusion Criteria
  • Patients aged between 40 and 70
  • Confirmed diagnosis of Bipolar Disorder or Schizophrenia according to Diagnostic and Statistical Manual of Mental Disorder IV (DSM-IV-TR)
  • Active smokers who currently consume at least 10 cigarettes a day, with a cumulative consumption of 10 packets/year or more.
Exclusion Criteria
  • Previous respiratory diagnosis of: asthma, cystic fibrosis, tuberculosis, simple chronic bronchitis, restrictive pulmonary disease or bronchiectasis
  • Acute respiratory symptoms
  • Heart disease or advanced oncological processes
  • Existence of a pathology which makes it advisable not to perform spirometry (recent pneumothorax, recent thoracic or abdominal surgery, aortic aneurysm, unstable angulation, retinal detachment, facial hemiparesis or oral/dental problems)
  • Patients who, due to their intellectual disability or mental pathology, do not understand or cannot be forced to perform spirometry
  • Clinical instability with results of over 14 points on the Hamilton Depression Rating Scale (HDRS), a Young Mania Rating Scale (YMRS) of over 6 or a Positive and Negative Syndrome Scale (PANSS) of over 70

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Experimental Grouppersonalized information about lung damageThis group will include personalized information about lung damage. After evaluating their COPD, the patients will be informed about its existence it so and staging. Depending on the damage found, the generation of motivation will focus on the different prevention methods. Likewise, after the motivation level is set, the patients will be offered the option of treatment and regular follow-up. The intervention will be strengthened by motivational messages, half of which are linked to the possibilities of preventing respiratory damage, sent to the patient's mobile phone via SMS during the 3 months after the face-to-face intervention. Patients without mobile phones will receive a call on their phone to convey the same messages.
Primary Outcome Measures
NameTimeMethod
COPD diagnosis12 month

Presence of COPD and staging and percentage of forced expiratory volume at one second (FEV1) compared with expected level

Smoking cessation12 months

Self-reported abstinence over the previous 7 days, confirmed by cooximetry with expired CO \<10 ppm

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Fernando Sarramea Crespo

🇪🇸

Cordoba, Spain

© Copyright 2025. All Rights Reserved by MedPath